Cellectar Biosciences vs Moleculin Biotech
CLRB and MBRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CLRB and MBRX compare
Moleculin Biotech is the larger company, worth 15 times as much as Cellectar Biosciences ($133M against $8.7M).
Cellectar Biosciences scores higher on the StockData Score (6 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CLRB | MBRX |
|---|---|---|
| Size and price | ||
| Market cap | $8.7M | $133M |
| Share price | $0.920 | $6.83 |
| Change, 1 year | −68.3% | −96.9% |
| Change, 5 years | −99.6% | −100.0% |
| Beta (5Y) | 1.73 | −1.10 |
| Employees | 11 | 150K |
| StockData Score | ||
| Total score | 6 (better) | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 11.5× |
| Profitability | ||
| Return on equity | −124% (better) | −524% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.66 (better) | 0.94 |
| Altman Z-score | −11.14 (better) | −11.19 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 36.8% | 0.05% |
| Held by insiders | 0.97% | 20.2% |
| Insider net buying, 12 months | $49.3K | – |
| Short interest, % of float | 2.3% | 0.35% |
Go deeper
- CLRB stock overview
- CLRB income statement
- CLRB valuation and score
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.